See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: Dec. 21, 2006

Renal Cell Cancer Obesity Osteoarthritis

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Renal Cell Cancer

This trial will determine whether sunitinib malate given on a 4/2 schedule (4 weeks on treatment, 2 weeks off treatment cycle) is any better at delaying progression of renal cell cancer than sunitinib malate given on a continuous dosing schedule. Volunteers with advanced renal cell carcinoma who have had no prior therapy for advanced disease in the last 12 months, or prior surgery or radiation therapy within the past four weeks, may be eligible.

The research sites are located across the United States.

More information

Please see http://www.centerwatch.com/patient/studies/cat680.html.

-----

Obesity

This research study will evaluate how sugar, protein, and fat affect appetite in school-age children. The study will last approximately five hours and involve a blood test. Children ages 7-11 may qualify, and compensation for participating will be provided.

The research site is in Lexington, Ky.

More information

Please see http://www.centerwatch.com/patient/studies/cat107.html.

-----

Osteoarthritis

This research study will evaluate the safety and effectiveness of Kadian NT when taken for chronic pain due to osteoarthritis of the hip or knee over a period of up to one year. Candidates 18-70 with a history of chronic moderate-to-severe pain for at least three months may qualify.

The research site is in Jupiter, Fla.

More information

Please see http://www.centerwatch.com/patient/studies/cat109.html.

-----

Copyright 2006 Thomson CenterWatch. All rights reserved.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.